Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells

被引:11
作者
Parsons, Heather A. [1 ]
Macrae, Erin R. [1 ]
Guo, Hao [1 ,2 ]
Li, Tianyu [1 ]
Barry, William T. [1 ,3 ]
Tayob, Nabihah [1 ]
Wulf, Gerburg M. [4 ]
Isakoff, Steven J. [5 ]
Krop, Ian E. [1 ]
机构
[1] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA
[2] IQVIA Biotech, Morrisville, NC USA
[3] Rho Inc, Durham, NC USA
[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
关键词
DISEASE PROGRESSION; PERIPHERAL-BLOOD; HER2; STATUS; SURVIVAL; AMPLIFICATION; RECEPTOR; POOR; TIME; GENE;
D O I
10.1200/PO.20.00461
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Human epidermal growth factor receptor 2 (HER2)-directed treatments improve outcomes for patients with HER2-positive metastatic breast cancer (MBC). Current identification of patients with HER2-positive disease relies on tumor tissue testing, which can be inaccurate because of tumor heterogeneity or tumor evolution. Circulating tumor cells (CTCs) are often present in patients with cancer. We hypothesized that HER2 assessment of CTCs in patients with HER2-negative breast cancer could identify a subset of patients with HER2-positive CTCs who could benefit from HER2-directed treatments. METHODS This was a single-arm, two-stage, phase II trial. Patients with HER2-negative progressive MBC with HER2-positive CTC (defined as HER2/CEP17 ratio >= 2.0 by fluorescence in situ hybridization), >= 1 prior chemotherapy regimen for MBC, and no prior vinorelbine received trastuzumab in combination with vinorelbine on days 1, 8, and 15 of a 21-day cycle. The primary end point was objective response rate. RESULTS From January 2013 to June 2014, we prospectively screened CTCs from patients with HER2-negative MBC. CTCs were detected in 201 of 311 patients (65%). The median number of CTCs was 10 (interquartile range, 3-57). Sixty-nine of 311 patients (22%) had HER2+ CTCs, with a median of three HER2+ CTCs (range 1-21). Twenty patients with HER2+ CTCs were treated on study. At data cutoff (January 13, 2017), no patients remained on study therapy. The objective response rate was 5% (95% CI, 0.1 to 24.9), with one of 20 patients experiencing a partial response. The clinical benefit rate was 20.0% (1 partial response and 3 stable diseases > 24 weeks, 95% CI, 5.7% to 43.7%). The median progression-free survival was 2.7 months. CONCLUSION CTC analysis of patients with HER2-negative MBC identifies a subset with HER2-amplified CTCs. However, clinical activity of an HER2-directed regimen in this population was low. The functional significance of HER2-positive CTCs remains uncertain.
引用
收藏
页码:896 / 903
页数:8
相关论文
共 32 条
[1]   THE PRODUCT OF THE HUMAN C-ERBB-2 GENE - A 185-KILODALTON GLYCOPROTEIN WITH TYROSINE KINASE-ACTIVITY [J].
AKIYAMA, T ;
SUDO, C ;
OGAWARA, H ;
TOYOSHIMA, K ;
YAMAMOTO, T .
SCIENCE, 1986, 232 (4758) :1644-1646
[2]  
Bauernhofer T, 2005, ONCOL REP, V13, P179
[3]   Circulating tumor cells versus imaging - Predicting overall survival in metastatic breast cancer [J].
Budd, G. Thomas ;
Cristofanilli, Massimo ;
Ellis, Mathew J. ;
Stopeck, Allison ;
Borden, Ernest ;
Miller, M. Craig ;
Matera, Jeri ;
Repollet, Madeline ;
Doyle, Gerald V. ;
Terstappen, Leon W. M. M. ;
Hayes, Daniel F. .
CLINICAL CANCER RESEARCH, 2006, 12 (21) :6403-6409
[4]   A Perspective on Cancer Cell Metastasis [J].
Chaffer, Christine L. ;
Weinberg, Robert A. .
SCIENCE, 2011, 331 (6024) :1559-1564
[5]   A review of the use of trastuzumab (Herceptin®) plus vinorelbine in metastatic breast cancer [J].
Chan, A. .
ANNALS OF ONCOLOGY, 2007, 18 (07) :1152-1158
[6]   TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE [J].
COUSSENS, L ;
YANGFENG, TL ;
LIAO, YC ;
CHEN, E ;
GRAY, A ;
MCGRATH, J ;
SEEBURG, PH ;
LIBERMANN, TA ;
SCHLESSINGER, J ;
FRANCKE, U ;
LEVINSON, A ;
ULLRICH, A .
SCIENCE, 1985, 230 (4730) :1132-1139
[7]   Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer [J].
Cristofanilli, M ;
Hayes, DF ;
Budd, GT ;
Ellis, MJ ;
Stopeck, A ;
Reuben, JM ;
Doyle, GV ;
Matera, J ;
Allard, WJ ;
Miller, MC ;
Fritsche, HA ;
Hortobagyi, GN ;
Terstappen, LWMM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) :1420-1430
[8]   Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J].
Cristofanilli, M ;
Budd, GT ;
Ellis, MJ ;
Stopeck, A ;
Matera, J ;
Miller, MC ;
Reuben, JM ;
Doyle, GV ;
Allard, WJ ;
Terstappen, LWMM ;
Hayes, DF .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) :781-791
[9]   Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer [J].
De Gregorio, Amelie ;
Friedl, Thomas W. P. ;
Huober, Jens ;
Scholz, Christoph ;
De Gregorio, Nikolaus ;
Rack, Brigitte ;
Trapp, Elisabeth ;
Alunni-Fabbroni, Marianna ;
Riethdorf, Sabine ;
Mueller, Volkmar ;
Schneeweiss, Andreas ;
Pantel, Klaus ;
Meier-Stiegen, Franziska ;
Jaeger, Bernadette ;
Hartkopf, Andreas ;
Taran, Florin-Andrei ;
Fasching, Peter A. ;
Janni, Wolfgang ;
Fehm, Tanja .
JCO PRECISION ONCOLOGY, 2017, 1 :1-12
[10]  
Fehm T, 2004, ANTICANCER RES, V24, P4205